Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of rhinitis/rhinoconjunctivitis in patients allergic to house dust mites.

A legfontosabb adatok

Ki végzi
Inmunotek S.L.
Hol
Coimbra, Lisboa, Lisbon és Porto (Portugália)Mind a 6 helyszín megnézéseMég 1 másik országban, 11 helyszínen
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
250 fő, tervezett
Kezdés
2025. nov. 18.
Várható befejezés
2029. ápr. 1.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. július 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat 12 és 65 év közötti, házipor-atka okozta közepesen súlyos vagy súlyos allergiás orrnyálkahártya-gyulladásban vagy orr- és kötőhártya-gyulladásban szenvedőket keres. Egyeseknek enyhe vagy közepesen súlyos, kontrollált asztmájuk is lehet.

Életkor
12–65 év
Nem
Nemtől függetlenül bárki részt vehet.
A betegség stádiuma
Közepesen súlyos vagy súlyos, tartós allergiás orrnyálkahártya-gyulladás vagy orr- és kötőhártya-gyulladás. A tünet- és gyógyszerpontszám (RCSMS) legalább 2 a 6-ból, legalább 10 napon át feljegyezve. Enyhe vagy közepesen súlyos, kontrollált asztma megengedett.
Korábbi kezelés
Az elmúlt 5 évben nem kaphatott immunterápiát Dermatophagoides pteronyssinus vagy Dermatophagoides farinae ellen. Más allergénnel végzett immunterápia nem folyhat. Nem kaphat biológiai vagy immunszuppresszív gyógyszert, kivéve a helyileg alkalmazottakat.
Biomarker vagy leletérték
Allergia Dermatophagoides pteronyssinus és/vagy Dermatophagoides farinae ellen. Negatív bőrpróba (skin prick test) penészgombákra.

A részvétel fő kizáró okai

  • Nem kontrollált vagy súlyos asztma
  • Kontrollált vagy nem kontrollált daganatos betegség
  • Terhes vagy szoptató nők
  • β-blokkoló (a helyileg alkalmazott kivételével) vagy ACE-gátló kezelés
  • Nem kontrollált autoimmun betegség vagy immunhiány

A regiszter feltételei, szó szerint

Mind a 38 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects who have signed and dated Informed Consent Form (ICF)
  • Subjects capable of complying with dosage regimen
  • Subjects must record symptoms and medication consumption in an electronic diary via smartphone (preferably) or in a paper diary
  • To be confirmed at visit 1 (V1). Only subjects who meet the following criteria will be eligible for randomization: 12. Subjects with a rhinitis/rhinoconjunctivitis combined symptom and medication score (RCSMS) ≥ 2 out of 6, recorded for at least 10 days, corresponding to moderate-to-severe allergic rhinitis/rhinoconjunctivitis (See Section 6.2)
  • Women of childbearing age must commit to using a highly effective contraception method during the trial and up to 1 months after the end of the investigational medicinal product. Such methods include combined (estrogen and progestogen containing) hormonal, contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), male condom, bilateral tubal occlusion, vasectomised partner, or sexual abstinence
  • Subjects capable of complying with dosage regimen
  • Subjects with negative skin prick test for moulds
  • Subjects must record symptoms and medication consumption in a n electronic diary (preferably) or in a paper diary
  • To be confirmed at visit 1 (V1) Only subjects who meet the following criteria will be eligible for randomization: Subjects with a rhinitis/rhinoconjunctivitis combined symptom and medication score (RCSMS) ≥ 2 out of 6, recorded for at least 10 days, corresponding to moderate-to-severe allergic rhinitis/rhinoconjunctivitis
  • Subjects with negative skin prick test for moulds
  • Women of childbearing age (i.e., following menarche and until postmenopause, defined as no menses for 12 months without an alternative medical cause, or non-subject to permanent sterilisation methods, such as hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) must confirm menarche and have a urine pregnancy test negative result before enrolling the study
  • Women of childbearing age must commit to using a highly effective contraception method during the trial and up to 1 months after the end of the investigational medicinal product. Such methods include combined (estrogen and progestogen containing) hormonal, contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), male condom, diaphragm used with spermicide, bilateral tubal occlusion, vasectomised partner, or sexual abstinence

Ki nem vehet részt

  • Use of drugs that could interfere with skin prick test reactions (e.g., antihistamines) within the deadlines set out in the protocol (See Section 9.2)
  • Subjects who have received previous immunotherapy to allergens under study (D. pteronyssinus and D. farinae) during the last 5 years or currently receiving immunotherapy with any other allergen
  • Subjects who required regular treatment with antihistamines and/or corticosteroids (systemic – oral or injectable-, topical, cutaneous, or inhaled) for other purposes than alleviating symptoms of allergic rhinitis, except temporal use (≤ 15 days) for diseases including common colds
  • Concurrent participation in other clinical trials or previous participation within 30 days prior to the screening/baseline visit
  • Subjects who have undergone any desensitisation process (e.g., oral immunotherapy [OIT], milk, or egg) except those in the maintenance phase since at least 12 months
  • Unstable subjects who have suffered a respiratory tract infection and/or asthma exacerbation within 4 weeks prior to the screening/baseline visit
  • Subjects with uncontrolled asthma, according to GINA 2023(2),asthma with poor symptom control (frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma) and/or frequent exacerbations (≥2/year) requiring oral corticosteroids (OCS), or serious exacerbations (≥1/year) requiring hospitalization
  • Asthmatic subjects with forced expiratory volume in the first second (FEV1) <80% despite pharmacological treatment. The result shall be valid up to 12 months prior to signing of informed consent (See Section 9.2)
  • Subjects on treatment with β-blockers, except those administered topically, or angiotensin-converting enzyme (ACE) inhibitors
  • Subjects on treatment with immunosuppressive (not including corticosteroids), except those administered topically, or biological drug
  • Subjects requiring regular treatment with systemic corticosteroids (oral or injectable) for the treatment of rhinitis/rhinoconjunctivitis and asthma. The regular use of topical, cutaneous, or inhaled corticosteroids for the treatment of the pathologies mentioned above and atopic dermatitis is permitted
  • Subjects who have suffered chronic urticaria, severe anaphylaxis, or family history of angioedema within 2 years prior to the screening/baseline visit
  • Subjects having any nasal condition (e.g., nasal polyp or non-allergic rhinitis) that could affect an appropriate evaluation of the efficacy and/or safety, according to investigator’s criteria
  • Subjects with history of serious systemic reactions, including food, Hymenoptera venom, drugs, etc
  • Those cases in which allergen-specific immunotherapy (AIT) would be a contraindication according to the criteria of European Allergy and Clinical Immunology Immunotherapy Subcommittee.(3)
  • Subjects with controlled or uncontrolled cancer
  • Subjects having any contraindication for the use of adrenaline (e.g., hyperthyroidism, heart disease, or hypertension) according to the investigator’s criteria
  • Subjects with other severe disease not related asthma or rhinitis/rhinoconjunctivitis that could interfere in the study treatment or the follow-up (e.g., epilepsy or nephropathy) according to investigator’s criteria
  • Subjects with uncontrolled autoimmune diseases (e.g., thyroiditis or lupus), tumoral diseases, or immunodeficiencies
  • Subjects that could not comply with the study protocol, according to investigator’s criteria, or have a serious mental illness
  • Subjects with known allergy to any of the components of the investigational medicinal products (IMPs) other than study allergens
  • Subjects with lower respiratory tract diseases, different from asthma, as emphysema, bronchiectasis, or chronic obstructive pulmonary disease
  • Subjects sensitised (positive skin prick test) to one or more pollens where the time interval between baseline visit (BV) and additional baseline visit (ABV) os more than 7 months
  • Breastfeeding or pregnant women
  • Subjects who are immediate family members of the investigator
  • Subjects with severe asthma, according to GINA 2023(2), on Step 4 or 5 treatment, who had poor symptom control and had good adherence and inhaler technique

Helyszínek itt: Portugália

Még 1 másik országban, 11 helyszínen

  • Unidade Local de Saúde de Coimbra, E.P.E.Coimbra, PortugáliaToborzás még nem indult
  • Unidade Local de Saúde de São José, E. P. E.Lisboa, PortugáliaToborzás még nem indult
  • Hospital Cuf Descobertas S.A.Lisbon, PortugáliaToborzás még nem indult
  • Unidade Local De Saude De Santa Maria E.P.E.Lisbon, PortugáliaToborzás még nem indult
  • Hospital CUF Porto S.A.Porto, PortugáliaToborzás még nem indult
  • Unidade Local De Saude De Santo Antonio E.P.E.Porto, PortugáliaToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective of this trial is to evaluate the clinical efficacy of EP-088_MM09 at 3,000 mTU/mL administered subcutaneously, compared to placebo in subjects aged 12 to 65 years old with moderate-to-severe persistent rhinitis/rhinoconjunctivitis with or without mild-to-moderate intermittent or persistent controlled asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial of efficacy and safety with Dermatophagoides pteronyssinus and Dermatophagoides farinae mannan-conjugated allergoids in patients with rhinitis/rhinoconjunctivitis, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae_MM09-SIT-063
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 9.
A regiszteradat frissítve
2026. július 2.